Medical treatment of metastasizing carcinoid tumors

World Journal of Surgery

Volumn 20, Issue 2, 1996, Pages 203-207

  Arnold, R ^a  

^a PHILIPPS UNIVERSITY MARBURG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE TRIPHOSPHATASE INHIBITOR; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; ALPHA INTERFERON; ALPHA2B INTERFERON; ANGIOPEPTIN; ANTINEOPLASTIC AGENT; CHLOROZOTOCIN; CISPLATIN; CYPROHEPTADINE; ETOPOSIDE; FENCLONINE; FLUOROURACIL; GLUCOCORTICOID; HISTAMINE H1 RECEPTOR ANTAGONIST; HISTAMINE H2 RECEPTOR ANTAGONIST; HYDROGEN POTASSIUM ADENOSINE TRIPHOSPHATASE; INTERFERON; LANSOPRAZOLE; LOPERAMIDE; METHYSERGIDE; NICOTINIC ACID; NONSTEROID ANTIINFLAMMATORY AGENT; OCTREOTIDE; OMEPRAZOLE; PHENOTHIAZINE DERIVATIVE; SEROTONIN ANTAGONIST; SOMATOSTATIN; SOMATOSTATIN DERIVATIVE; STREPTOZOCIN; UNINDEXED DRUG;

ALOPECIA; BONE MARROW TOXICITY; CANCER HORMONE THERAPY; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CARCINOID SYNDROME; CLINICAL FEATURE; CLINICAL TRIAL; CONFERENCE PAPER; DIARRHEA; DRUG EFFICACY; GASTRINOMA; HUMAN; HYPERGLYCEMIA; INTRAVENOUS DRUG ADMINISTRATION; LIVER METASTASIS; MULTICENTER STUDY; ORAL DRUG ADMINISTRATION; PELLAGRA; PHASE 2 CLINICAL TRIAL; STEATORRHEA; SUBCUTANEOUS DRUG ADMINISTRATION; THYROTOXICOSIS; VOMITING; WATER INTOXICATION; ZOLLINGER ELLISON SYNDROME;

CARCINOID TUMOR; CLINICAL TRIALS; COMBINED MODALITY THERAPY; DUODENAL NEOPLASMS; EMBOLIZATION, THERAPEUTIC; GASTRINOMA; GASTROINTESTINAL NEOPLASMS; HORMONE ANTAGONISTS; HUMANS; MALIGNANT CARCINOID SYNDROME; PROSPECTIVE STUDIES; PROTON PUMPS; SOMATOSTATIN;

EID: 0030032568     PISSN: 03642313     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002689900031     Document Type: Conference Paper

References (33)

1. Creutzfeldt, W.: Endocrine tumors of the pancreas. In The Diabetic Pancreas, E. Arquilla, B.W. Volks, editors. New York, Plenum, 1985. pp. 543-561
2. Oberndorfer, S.: Karzinoide Tumoren des Dünndarms. Frankfurt Pathol. 1:426, 1907
3. Williams, E.D., Sandler, M.: The classification of carcinoid tumors. Lancet 1:238, 1963
4. DeLellis, R.A., Dayal, Y., Wolfe, HJ.: Carcinoid tumors: changing concepts and new perspectives. Am. J. Surg. Pathol. 8:295, 1984
5. Creutzfeldt, W.: Historial background and natural history of carcinoids. Digestion 55(Suppl. 3):3, 1994
6. + -ATPase. Nature 290:159, 1981
7. Clissold, S.P., Campoli-Richards, D.M.: Omeprazole. Drugs 32:15, 1986
8. Frucht, H, Maton, P.N., Jensen, R.T.: The use of omeprazole in patients with Zollinger-Ellison syndrome. Dig. Dis. Sci. 36:394, 1993
9. Metz, D C., Jensen, R.T.: Advances in gastric anti-secretory therapy in Zollinger-Ellison syndrome: Front. Gastrointest. Res. 23:240, 1995
10. Metz, D.B., Pisegna, J.R., Ringham, G.L., et al.: Prospective study of the efficacy and safety of lansoprazole in Zollinger-Ellison syndrome. Dig. Dis. Sci. 38:245, 1993
11. Solcia, E., Capella, C., Fiocca, R., Rindi, G., Rosai, J.: Gastric argyrophil carcinoidosis in patients with Zollinger-Ellison syndrome due to type 1 multiple endocrine neoplasia: a newly recognized association. Am. J. Surg. Pathol. 14:503, 1990
12. Lehy, T, Cadiot, G., Mignon, M., Ruszniewski, P., Bonfils, S.: Influence of multiple endocrine neoplasia type 1 on gastric endocrine cells in patients with the Zollinger-Ellison syndrome. Gut 33:1275, 1992
13. Vinik, A.I., Shih-tzer, T., Moattari, A.R., Cheung, P.: Somatostatin analogue (SMS 201-995) in patients with gastrinomas. Surgery 104: 834, 1988
14. Ruszniewski, P., Laucournet, H., Elounar-Blanc, L., Mignon, M., Bonfils, S.: Long-acting somatostatin (SMS 201-995) m the management of Zollinger-Ellison syndrome: evidence for sustained efficacy. Pancreas 3:145, 1988
15. Kvols, L.K., Moertel, C.G., O'Connel, M.J., Schutt, A.J., Rubin, J., Hahn, R.G.: Treatment of the malignant carcinoid syndrome: evaluation of a long-acting somatostatin analogue. N. Engl. J. Med. 315:663, 1986
16. Vinik, A., Moattari, A.R.: Use of somatostatin analog in management of carcinoid syndrome. Dig. Dis. Sci. 34(Suppl.):149, 1989
17. Buchanan, K.D.: Effects of sandostatin on neuroendocrine tumors of the gastrointestinal system. Recent Results Cancer Res. 129:45, 1993
18. Reichlin, S.: Somatostatin. N. Engl. J. Med. 309:1495, 1983
19. Reichlin, S.: Somatostatin. N. Engl. J. Med. 309:1556, 1983
20. Moertel, C.G., Kvols, L.K., Rubin, J.: A study of cyproheptadine in the treatment of metastatic carcinoid tumor and the malignant carcinoid syndrome. Cancer 67:33, 1991
21. Dowling, R.H., Hussaini, S.H., Murphy, G.M.: Gallstones during octreotide therapy. Metabolism 47(Suppl. 2):22, 1992
22. Arnold, R., Trautmann, M.E., Creutzfeldt, W., et al.: Somatostatin analogue octreotide and inhibition of tumor growth in metastatic endocrine gastroentero-pancreatic tumors. Gut (in press)
23. Halma, C., Jansen, J.B., Janssens R., Griffionen, G., Lamers, C.B.H.W.: Life-threatening water intoxication during somatostatin therapy. Ann. Intern. Med. 107:518, 1987
24. Arnold, R., Neuhaus, C., Benning, R., et al.: Somatostatin analog Sandostatin and inhibition of tumor growth in patients with metastatic endocrine gastroenteropancreatic tumors. World J. Surg. 17:511, 1993
25. Evers, B.M., Parekh, D., Townsend, C.M., Thompson, J.C.: Somatostatin and analogues in the treatment of cancer: a review. Ann. Surg. 213:190, 1991
26. Liebow, C., Reilly, C., Serrano, M., Schally, A.V.: Somatostatin analogues inhibit growth of pancreatic cancer by stimulating tyrosine phosphatase. Proc. Natl. Acad Sci. U.S.A. 86:2003, 1989
27. Kraenzlin, M.E., Ch'ng, J.C., Wood, S.M., Bloom, S.R.: Can inhibition of hormone secretion be associated with endocrine tumor shrinkage? Lancet 2:1501, 1983
28. Kraenzlin, M.E., Ch'ng, I.L.C., Wood, S.M., Carr, D.D.: Long term treatment of a VIPoma with somatostatin analogue resulting in remission of symptoms and possible shrinkage of metastases. Gastroenterology 88:185, 1985
29. Clements, D., Elias, E.: Regression of metastatic VIPoma with somatostatin analogue SMS 201-995. Lancet 1:874, 1985
30. Shepherd, J.J., Senator, G.B.: Regression of liver metastases in patients with gastrin-secreting tumor treated with SMS 201-995. Lancet 1:574, 1986
31. Wiedenmann, B., Räth, U., Rädsch, R., Becker, F., Kommerell, B.: Tumor regression of an ileal carcinoid under the treatment with the somatostain analogue SMS 201-995. Klin. Wochenschr. 66:75, 1988
32. Creutzfeldt, W., Bartsch, H.H., Jacubaschke, U., Stöckmann, F.: Treatment of gastrointestinal endocrine tumor with interferon-alpha and octreotide. Acta Oncol. 30:529, 1991
33. Saltz, L., Trochanowsky, B., Buckley, M., et al.: Octreotide as an antineoplastic agent in the treatment of functional and non-functional neuro-endocrine tumors. Cancer 72:244, 1993